Activation of KRAS mediates resistance to targeted therapy in MET exon 14 mutant non-small cell lung cancer

PURPOSE: MET exon 14 splice site alterations that cause exon skipping at the mRNA level (METex14) are actionable oncogenic drivers amenable to therapy with MET tyrosine kinase inhibitors (TKI); however, secondary resistance eventually arises in most cases while other tumors display primary resistanc...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Clin Cancer Res
Main Authors: Suzawa, Ken, Offin, Michael, Lu, Daniel, Kurzatkowski, Christopher, Vojnic, Morana, Smith, Roger S., Sabari, Joshua K., Tai, Huichun, Mattar, Marissa, Khodos, Inna, de Stanchina, Elisa, Rudin, Charles M., Kris, Mark G., Arcila, Maria E., Lockwood, William W., Drilon, Alexander, Ladanyi, Marc, Somwar, Romel
Format: Artigo
Sprog:Inglês
Udgivet: 2018
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6377821/
https://ncbi.nlm.nih.gov/pubmed/30352902
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-1640
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker